PXL/HO/Cir-075/2023-24                                                                            Date: 14.11.2023

Hyderabad

Dear Sir/Madam

Subject: Saudi Food and Drug Authority (SFDA) Collaboration with Pharmexcil

We are pleased to inform you that the Saudi Arabia embassy in New Delhi hosted a Roundtable interactive meeting of  H.E Prof. Hishan S Aljadhey, CEO of Saudi Food & Drug Authoritywith leading Indian pharma companies on 2^nd Nov 2023 in New Delhi.  During the Round table, it is understood that Saudi Food and Drug Authorities will provide the following incentives on the attached list of productswhich are unregistered and unavailable in Kingdom of Saudi Arabia. 

·         Fees reduction for registration and inspection.

·         Flexibility in pricing and giving the products price advantage and stabilization.

·         Registration Priority.

·         Support and exemption from some technical Requirements.

Attached please find the Presentation made during the round table discussionas well as the List of the unregistered and unavailable products received from the SFDA.

In an attempt to build an end-to-end partnership with Indian respected pharmaceutical companies, the SFDA is seeking information mentioned in the attached file (on the number of products manufactured by the company, products registered with SFDA, USFDA & EMA and details of the  local distributors in Saudi Arabia etc ).  You are requested to kindly provide the information latest by 21^st Nov 2023 to director.rodelhi@pharmexcil.com

Member companies may take advantage of this unique opportunity for expansion of their business portfolio in the GCC region and share the response in attached Excel sheet as soon as possible

With regards,

Udaya Bhaskar

Director General

Encl: List of Products